NIH R61/R33: Phased Innovation Award

R61 Exploratory Phase: Milestones Instead of a Finished Plan

The R61 Specific Aims section (1 page) defines 2-3 feasibility-focused aims built around explicit, measurable go/no-go milestones, and must justify how meeting those milestones enables the R33 transition. The Research Strategy Approach section carries the real weight of the application:

• Explicit go/no-go milestones with quantitative thresholds — objective and measurable (e.g. accuracy %, sensitivity/specificity, reproducibility, performance benchmarks), not qualitative goals
• Timeline with interim decision points — typically 2 years or less, structured around when each milestone will be assessed
• Risk mitigation and alternative strategies — what happens if a milestone is at risk
• A transition plan — outlining specifically how achieving the milestones enables the R33 phase
• Innovation justification — the Research Strategy Innovation section must explain why R61 scale and timeline are warranted for this feasibility work, including why the project needs R61 rather than a smaller R21

No Preliminary Data Penalty in R61

R61 review explicitly does not penalize the absence of preliminary data. This mirrors R61's purpose: it exists to fund early feasibility testing before a full evidentiary base exists. Reviewers instead concentrate on whether the milestones themselves are SMART -- specific, measurable, achievable, relevant, and time-bound -- since those milestones, once negotiated with NIH program staff, become binding terms of the award. Vague or unmeasurable milestones are treated as a significant weakness, not a stylistic issue.

R33 Development Phase: Building on Achieved Milestones

The R33 phase is only entered upon successful R61 transition. Its Specific Aims section states 2-4 development aims that build on R61 results, explicitly referencing the R61 milestones that were achieved and defining endpoints and performance metrics for success. The Research Strategy Approach section must summarize the achieved R61 milestones as the transition justification, then provide detailed development and validation methods, performance metrics, risk mitigation, and a timeline of typically 3 years or less.

• Preliminary/milestone data are expected in R33 — unlike R61, R33 review treats R61 milestone-attainment data (or, for standalone R33 applications, comparably strong preliminary data) as required evidence that the project is ready to scale up
• Rigor and Feasibility matter more in R33 than R61 — reviewers assess the full development plan and whether it credibly builds on R61-phase results
• Track record against R61 milestones counts — the Investigator(s) and Environment assessment considers performance against the R61 milestones if this is a continuation

Review Criteria: Simplified Peer Review Framework, Applied Per Phase

Both R61 and R33 are reviewed under NIH's Simplified Peer Review Framework, which uses three factors instead of the traditional five NIH criteria. The factor emphasis differs meaningfully between the two phases:

• Factor 1, Importance of the Research (Significance and Innovation) — in R61, reviewers weight Innovation heavily, since R61 exists to develop genuinely new approaches rather than incremental extensions; in R33, the question shifts to whether the work, once developed, addresses an important problem at scale, translating the innovation established in R61 into a fuller research program
• Factor 2, Rigor and Feasibility (Approach) — in R61, the most important element is whether the proposed milestones are SMART and would credibly justify R33 transition, with no penalty for missing preliminary data; in R33, this factor carries even more weight and is assessed on the full development plan and how credibly it builds on R61-phase results
• Factor 3, Expertise and Resources (Investigator(s) and Environment) — not scored numerically in either phase; assessed as "appropriate" or with specific gaps identified. R61 asks whether the team can execute developmental/pilot work, with experience in adjacent areas counting; R33 also weighs the team's track record against the R61 milestones

Shared Application Elements Across Both Phases

Both R61 and R33 applications follow the same overall structure: a Project Summary/Abstract (30 lines), a three-sentence Project Narrative on public health relevance, Specific Aims (1 page), a Research Strategy covering Significance, Innovation, and Approach, Biographical Sketches (Common Forms via SciENcv for due dates on or after January 25, 2026), a Data Management and Sharing Plan, and standard supporting attachments such as Facilities, Equipment, and budget documentation. The Approach section is substantially more detailed in R33 (reflecting a longer, larger-scale development plan) than in R61 (which is scoped to feasibility testing and milestone measurement).